Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer

Cancer

Volumn 110, Issue 1, 2007, Pages 215-223

  Wu, Yi Hui ^a   Cheng, Ya Wen ^a   Tsai, Jinghua Chang ^a   Wu, Tzu Chin ^a,b   Chen, Chih Yi ^c   Lee, Huei ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Non small cell lung cancer (NSCLC); Prognosis; Real time reverse transcriptase polymerase chain reaction (RT PCR); Xeroderma pigmentosum complementary group C (XPC) mRNA

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; MATRIGEL; MESSENGER RNA; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR E2F1; XERODERMA PIGMENTOSUM GROUP C PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; DNA-BINDING PROTEINS; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; S-PHASE KINASE-ASSOCIATED PROTEINS;

EID: 34250877413     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22743     Document Type: Article

References (49)

1. Department of Health, Executive Yuan, Republic of China. Health Statistics, 2002. Yuan, Republic of China: Department of Health; 2002.
2. Department of Health, Executive Yuan, Republic of China. Health Statistics, 2003. Yuan, Republic of China: Department of Health; 2003.
3. Davies AM, Chansky K, Lau DH, et al. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol. 2006;24:5242-5246.
4. Huber RM, Flentje M, Schmidt M, et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the bronchial carcinoma therapy group. J Clin Oncol. 2006;24:4397-4404.
5. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. J Clin Oncol. 2005;23:3235-3242.
6. Cheng YW, Hsieh LL, Lin PP, et al. Gender difference in DNA adduct levels among nonsmoking lung cancer patients. Environ Mol Mutagen. 2001;37:304-310.
7. Cheng YW, Lee H. Environmental exposure and lung cancer: an example of Taiwanese female lung cancer. J Environ Sci Health part C C. 2003;21:1-28.
8. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1:22-33.
9. Wei Q, Cheng L, Amos CI, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst. 2000;92:1764-1772.
10. Wei Q, Cheng L, Hong WK, et al. Reduced DNA repair capacity in lung cancer patients. Cancer Res. 1996;56:4103-4107.
11. Chaney SG, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst. 1996; 88:1346-1360.
12. Wood RD, Mitchell M, Lindahl T. Human DNA repair genes. Mutat Res. 2005;577:275-283.
13. Wang G, Chuang L, Zhang X, et al. The initiative role of XPC protein in cisplatin DNA damaging treatment-mediated cell cycle regulation. Nucleic Acids Res. 2004;32: 2231-2240.
14. Wang G, Dombkowski A, Chuang L, et al. The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response. Cell Res. 2004;14:303-314.
15. Azzam EI, Nagasawa H, Yu Y, et al. Cell cycle deregulation and xeroderma pigmentosum group C cell transformation. J Invest Dermatol. 2002;119:1350-1354.
16. Cheo DL, Burns DK, Meira LB, et al. Mutational inactivation of the xeroderma pigmentosum group C gene confers predisposition to 2-acetylaminofluorene-induced liver and lung cancer and to spontaneous testicular cancer in Trp53-/- mice. Cancer Res. 1999;59:771-775.
17. Hollander MC, Philburn RT, Patterson AD, et al. Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis. Proc Natl Acad Sci USA. 2005;102:13200-13205.
18. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425-479.
19. Pagano M, Tam S, Theodoras A, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995;269: 682-685.
20. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol. 2003;13:41-47.
21. Osoegawa A, Yashino I, Tanaka S, et al. Regulation of p27 by S-phase kinase-associated protein is associated with aggressiveness in non-small-cell lung cancer. J Clin Oncol. 2004;22:4165-4173.
22. Shih JY, Yang SC, Hong TM, et al. Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells. J Natl Cancer Inst. 2001;93:1392-1400.
23. Chang JT. An economic and efficient method of RNAi vector constructions. Anal Biochem. 2004;334:199-200.
24. Zhang L, Wang C. F-box protein Skp2: a novel transcriptional target of E2F. Oncogene. 2006;25:2615-2627.
25. Ko JL, Cheng YW, Chang SL, et al. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer. Int J Cancer. 2000;89:265-270.
26. Muller-Tidow C, Diederichs S, Bulk E, et al. Identification of metastasis-associated receptor tyrosine kinase in non-small cell lung cancer. Cancer Res. 2005;65:1778-1782.
27. Buttitta F, Martella C, Barassi F, et al. Int6 expression can predict survival in early-stage non-small cell lung cancer patients. Clin Cancer Res. 2005;11:3198-3204.
28. Ferraro B, Bepler G, Sharma S, et al. EGR1 predicts PTEN and survival in patients with non-small cell lung cancer. J Clin Oncol. 2005;23:1921-1926.
29. Sher YP, Shih JY, Yang PC, et al. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes. Clin Cancer Res. 2005;11:173-179.
30. Yuan A, Yu CJ, Shun CT, et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer. 2005; 115:545-555.
31. Adimoolam S, Ford JM. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci U S A. 2002;99:12985-12990.
32. Shen H, Spitz MR, Qiao Y, et al. Smoking, DNA repair capability and risk of nonsmall cell lung cancer. Int J Cancer. 2003;107:84-88.
33. Cheng YW, Chiou HL, Sheu GT, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res. 2001; 61:2799-2803.
34. INK4a promoter hypermethylation in human papillomavirus-infected female lung cancer in Taiwan. Int J Cancer. 2005;113:440-445.
35. Ko YC, Cheng SC, Lee CH, et al. Chinese food cooking and lung cancer in Taiwan. Am J Epidemiol. 2001;51:140-147.
36. Yang SC, Jenq SN, Kang ZC, et al. Identification of benzo[a]pyrene 7, 8-diol 9,10-epoxide N2-deoxyguanosine in human lung adenocarcinoma cells exposed to cooking oil fumes from frying fish under domestic conditions. Chem Res Toxicol. 2000;13:1046-1050.
37. Chen KY, Chang CH, Yu CJ, et al. Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma. Cancer. 2005;103: 2566-2574.
38. Sugasawa K, Masutani C, Uchida A, et al. HHR23B, a human Rad23 homolog, stimulates XPC protein in nucleotide excision repair in vitro. Mol Cell Biol. 1996;16:4852-4861.
39. Wang Q, Zhu Q, Wani MA, et al. Tumor suppressor p53 dependent recruitment of nucleotide excision repair factors XPC and TFIIH to DNA damage. DNA Repair. 2003;2:483-499.
40. Adimoolam S, Ford JM. p53 and regulation of DNA damage recognition during nucleotide excision repair. DNA Repair. 2003;2:947-954.
41. Quinlan DC, Davidson AG, Summer CL, et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 1992;52:4828-4832.
42. Esposito V, Baldi A, De-Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997;57:3381-3385.
43. Tsukamoto S, Sugio K, Sakada T, et al. Reduced expression of cell-cycle regulator p27Kip1 correlates with a shortened survival in non-small cell cancer. Lung Cancer. 2001;34:83-90.
44. Shigemasa K, Gu L, O'Brien TJ, et al. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Clin Cancer Res. 2003;9:1756-1763.
45. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 2000;183: 10-17.
46. Kudo Y, Kitajima S, Sato S, et al. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res. 2001;61:7044-7047.
47. Masuda T, Inoue H, Sonoda H, et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 2002;62:3819-3825.
48. Shigemasa K, Gu L, O'Brien TJ, et al. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma. Clin Cancer Res. 2003;9:1756-1763.
49. Osoegawa A, Yoshino I, Tanaka S, et al. Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. J. Clin Oncol. 2004;22:4165-4173.